NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell therapy, with pipeline programs targeting oncology and neurodegenerative diseases. The company entered public markets through its business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition Holdings IV LLC that completed its initial public offering in 2022. The de-SPAC merger closed in 2023, after which NKGen began filing as a combined public entity under the NKGN ticker on Nasdaq. The Form 10-Q filed August 14, 2023 reflects the company's early post-merger reporting period in the healthcare biotechnology sector. Sign up at SpacDesk for complete filing history, sponsor profiles, and deal analytics on NKGN and hundreds of other SPAC transactions.